ABSTRACT
Patients who are immunocompromised or have cognitive or physical disabilities are at a higher risk of being affected with infections such as crusted scabies. This is a rare skin hyperinfestation by Sarcoptes scabiei var. hominis. The main characteristic of this dermatosis is a thick crust due to the high concentration of mites; in addition, other manifestations such as papules, excoriations, and burrows may be absent. In severe cases, thick yellow-brown crusts and plaques with deep fissures are present. Diagnosis can be made by observing mites, ova, or feces from skin scrapings. Multiple therapies can be used in patients with this condition. Management with patient isolation is important to prevent institutional outbreaks. This disease can have high mortality, primarily due to sepsis. Awareness of this condition and its serious consequences is important to reduce its mortality and morbidity.
Subject(s)
Sarcoptes scabiei/growth & development , Scabies/diagnosis , Scabies/pathology , Skin/pathology , Skin/parasitology , Adult , Animals , Female , HumansABSTRACT
Capecitabine is a prodrug used primarily as a chemotherapeutic agent. Despite its good tolerance, it has several adverse effects, including the appearance of eruptive nevi. We present the case of a patient, with a history of EC IV breast adenocarcinoma and superficial extension melanoma, which developed 2 weeks after the start of therapy with capecitabine multiple eruptive palmoplantar pigmented lesions, with diverse benign dermatoscopic patterns. With the increasing incidence of solid tumors, these agents are being more used. It is important that the treating physician knows its adverse effects and apply non-invasive diagnostic tools like dermoscopy to avoid unnecessary biopsies.
La capecitabina es un profármaco utilizado sobre todo como medicamento quimioterapéutico. A pesar de su buena tolerancia, produce diversos efectos adversos como la aparición de nevos eruptivos. Se presenta el caso de una paciente, con antecedentes de adenocarcinoma de mama (EC IV) y melanoma de extensión superficial, que desarrolló dos semanas posteriores al inicio del tratamiento con capecitabina múltiples lesiones eruptivas pigmentadas palmoplantares, con patrones variados benignos a la dermatoscopia. Con el incremento de las neoplasias sólidas, estos agentes se utilizan cada vez más. Es importante que el médico tratante conozca sus efectos adversos y aplique herramientas diagnósticas no invasivas como la dermatoscopia para evitar biopsias innecesarias.
